Notably, trastuzumab-deruxtecan (T-DXd, DS-8201), another ADC agent consisting of an anti-HER2 antibody and a topoisomerase I inhibitor, demonstrated promising outcomes in HER2 mutant NSCLC in a phase II study [295]. Here, ERBB2 is linked to non-small cell lung carcinoma.